Cargando…

Signaling Network Response to α-Particle–Targeted Therapy with the (225)Ac-Labeled Minigastrin Analog (225)Ac-PP-F11N Reveals the Radiosensitizing Potential of Histone Deacetylase Inhibitors

α-particle emitters have recently been explored as valuable therapeutic radionuclides. Yet, toxicity to healthy organs and cancer radioresistance limit the efficacy of targeted α-particle therapy (TAT). Identification of the radiation-activated mechanisms that drive cancer cell survival provides opp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, Yun, Imobersteg, Stefan, Frank, Stephan, Blanc, Alain, Chiorazzo, Tanja, Berger, Philipp, Schibli, Roger, Béhé, Martin P., Grzmil, Michal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society of Nuclear Medicine 2023
Materias:	Basic Science Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241010/ https://www.ncbi.nlm.nih.gov/pubmed/36732057 http://dx.doi.org/10.2967/jnumed.122.264597

Ejemplares similares

Evaluation of Actinium-225 Labeled Minigastrin Analogue [(225)Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy
por: Qin, Yun, et al.
Publicado: (2020)

[(225)Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [(225)Ac]Ac-PSMA-617
por: Busslinger, Sarah D., et al.
Publicado: (2022)

Therapeutic Response of CCKBR-Positive Tumors to Combinatory Treatment with Everolimus and the Radiolabeled Minigastrin Analogue [(177)Lu]Lu-PP-F11N
por: Grzmil, Michal, et al.
Publicado: (2021)

Cure of Disseminated Human Lymphoma with [(225)Ac]Ac-Ofatumumab in a Preclinical Model
por: Longtine, Mark S., et al.
Publicado: (2023)

Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [(177)Lu]Lu-PP-F11N
por: Grzmil, Michal, et al.
Publicado: (2020)

Synthesis and Stability of Actinium-225 Endohedral Fullerenes, (225)Ac@C(60)
por: Mwakisege, Jofa Gideon, et al.
Publicado: (2020)

Improved Tumor-Targeting with Peptidomimetic Analogs of Minigastrin (177)Lu-PP-F11N
por: Grob, Nathalie M., et al.
Publicado: (2021)

Resonant laser ionization and mass separation of $^{225}$Ac
por: Johnson, Jake D, et al.
Publicado: (2023)

Comparison of the biodistribution of $^{225}$Ac and radiolanthanides as citrate complexes
por: Beyer, Gerd-Jürgen, et al.
Publicado: (1990)

The application of poorly crystalline silicotitanate in production of (225)Ac
por: Fitzsimmons, Jonathan, et al.
Publicado: (2019)

Development of (225)Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences
por: Robertson, Andrew Kyle Henderson, et al.
Publicado: (2018)

Resonant laser ionization and mass separation of (225)Ac
por: Johnson, Jake D., et al.
Publicado: (2023)

Estimating (225)Ac yield in thorium metal targets
por: Rahmani, M., et al.
Publicado: (2023)

(225)Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic
por: Rubira, Léa, et al.
Publicado: (2023)

(225)Ac-MACROPATATE: A Novel α-Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors
por: King, A. Paden, et al.
Publicado: (2023)

Evaluation of (134)Ce/(134)La as a PET Imaging Theranostic Pair for (225)Ac α-Radiotherapeutics
por: Bobba, Kondapa Naidu, et al.
Publicado: (2023)

Tandem Isotope Therapy with (225)Ac- and (177)Lu-PSMA-617 in a Murine Model of Prostate Cancer
por: Meyer, Catherine, et al.
Publicado: (2023)

Estimation of relative biological effectiveness of (225)Ac compared to (177)Lu during [(225)Ac]Ac-PSMA and [(177)Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS
por: Rumiantcev, Mikhail, et al.
Publicado: (2023)

New measurement of exotic decay of $^{225}$Ac by $^{14}$C emission
por: Guglielmetti, A, et al.
Publicado: (2001)

Cyclotron production of (225)Ac from an electroplated (226)Ra target
por: Nagatsu, Kotaro, et al.
Publicado: (2021)

Ac-EAZY! Towards GMP-Compliant Module Syntheses of (225)Ac-Labeled Peptides for Clinical Application
por: Pretze, Marc, et al.
Publicado: (2021)

First In Vivo and Phantom Imaging of Cyclotron-Produced (133)La as a Theranostic Radionuclide for (225)Ac and (135)La
por: Nelson, Bryce J.B., et al.
Publicado: (2022)

α-Zirconium(IV) Phosphate: Static Study of (225)Ac Sorption in an Acidic Environment and Its Kinetic Sorption Study Using (nat)Eu as a Model System for (225)Ac
por: Ondrák, Lukáš, et al.
Publicado: (2023)

Towards reliable production of 225Ac for medical applications: Systematic analysis of the production of Fr, Ra and Ac beams.
por: Dockx, Kristof, et al.
Publicado: (2017)

Initial Findings on the Use of [(225)Ac]Ac-DOTATATE Therapy as a Theranostic Application in Patients with Neuroendocrine Tumors
por: Demirci, Emre, et al.
Publicado: (2023)

Development of (225)Ac Production from Low Isotopic Dilution (229)Th
por: Camacaro, Jose F., et al.
Publicado: (2023)

Development of [(225)Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC
por: Hooijman, Eline L., et al.
Publicado: (2021)

Preliminary Therapy Evaluation of (225)Ac-DOTA-c(RGDyK) Demonstrates that Cerenkov Radiation Derived from (225)Ac Daughter Decay Can Be Detected by Optical Imaging for In Vivo Tumor Visualization
por: Pandya, Darpan N., et al.
Publicado: (2016)

Nuclear structure effects in the exotic decay of $^{225}$Ac via $^{14}$C emission
por: Bonetti, R, et al.
Publicado: (1992)

The influence of EDTMP-concentration on the biodistribution of radio-lanthanides and $^{225}$Ac in tumor bearing mice
por: Beyer, Gerd-Jürgen, et al.
Publicado: (1996)

Nuclear structure effects in the exotic decay of $^{225}$Ac via $^{14}$C emission
por: Bonetti, R, et al.
Publicado: (1993)

Mass separation of 225Ac for medical applications: first proof of principle at CERN-MEDICIS
por: Heines, Michael
Publicado: (2021)

The in vivo fate of (225)Ac daughter nuclides using polymersomes as a model carrier
por: Kruijff, R. M. de, et al.
Publicado: (2019)

Image-based dosimetry for (225)Ac-PSMA-I&T therapy using quantitative SPECT
por: Gosewisch, A., et al.
Publicado: (2020)

CKD After 225Ac-PSMA617 Therapy in Patients With Metastatic Prostate Cancer
por: Pelletier, Karyne, et al.
Publicado: (2020)

A suitable time point for quantifying the radiochemical purity of (225)Ac-labeled radiopharmaceuticals
por: Kelly, James M., et al.
Publicado: (2021)

Feasibility of a novel photoproduction of (225)Ac and (227)Th with natural thorium target
por: Ju, Kwangho, et al.
Publicado: (2022)

Treatment of Prostate Cancer with CD46-targeted (225)Ac Alpha Particle Radioimmunotherapy
por: Bidkar, Anil P., et al.
Publicado: (2023)

Dose escalation study of targeted alpha therapy with [(225)Ac]Ac-DOTA-substance P in recurrence glioblastoma – safety and efficacy
por: Królicki, Leszek, et al.
Publicado: (2021)

Development of [(225)Ac]Ac-DOTA-C595 as radioimmunotherapy of pancreatic cancer: in vitro evaluation, dosimetric assessment and detector calibration
por: Hull, Ashleigh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g3n6sb0hvsm46u19jqepuhmsfu